Quest Diagnostics Incorporated (NYSE:DGX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
matter presented to the stockholders at the 2017 Annual Meeting
of Stockholders of Quest Diagnostics Incorporated (the
“Company”).
elected for terms expiring at the 2018 Annual Meeting of
Stockholders, by the following votes:
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
|
|
|
|
|
|
|
|
|
Jenne K. Britell, Ph.D.
|
106,312,534
|
|
5,067,420
|
|
218,841
|
|
9,952,073
|
|
|
|
|
|
|
|
|
|
|
Vicky B. Gregg
|
108,676,223
|
|
2,750,392
|
|
172,183
|
|
9,952,070
|
|
|
|
|
|
|
|
|
|
|
Jeffrey M. Leiden, M.D., Ph.D.
|
108,448,707
|
|
2,813,269
|
|
336,821
|
|
9,952,071
|
|
|
|
|
|
|
|
|
|
|
Timothy L. Main
|
107,175,221
|
|
4,081,331
|
|
342,246
|
|
9,952,070
|
|
|
|
|
|
|
|
|
|
|
Gary M. Pfeiffer
|
105,412,335
|
|
5,856,327
|
|
330,136
|
|
9,952,070
|
|
|
|
|
|
|
|
|
|
|
Timothy M. Ring
|
103,212,338
|
|
8,045,782
|
|
340,678
|
|
9,952,070
|
|
|
|
|
|
|
|
|
|
|
Stephen H. Rusckowski
|
102,795,186
|
|
7,568,467
|
|
1,235,146
|
|
9,952,069
|
|
|
|
|
|
|
|
|
|
|
Daniel C. Stanzione, Ph.D.
|
102,001,423
|
|
8,027,809
|
|
1,569,567
|
|
9,952,069
|
|
|
|
|
|
|
|
|
|
|
Gail R. Wilensky, Ph.D.
|
103,441,455
|
|
6,704,598
|
|
1,452,745
|
|
9,952,070
|
compensation disclosed in the Company’s 2017 Proxy Statement was
approved by the following votes:
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
102,318,798
|
|
8,815,048
|
|
464,762
|
|
9,952,260
|
all of which were entitled to vote at the Meeting, voted as follows
in respect of the frequency of the stockholder advisory vote to
approve executive officer compensation:
|
3 Years
|
|
2 Years
|
|
1 Year
|
|
Abstain
|
|
Broker Non-Vote
|
|
17,075,091
|
|
264,847
|
|
94,039,485
|
|
219,184
|
|
9,952,261
|
independent registered public accounting firm for 2017 was
approved by the following votes:
|
For
|
|
Against
|
|
Abstain
|
|
|
|
116,502,215
|
|
4,895,916
|
|
152,737
|
|
|
Long-Term Incentive Plan for Non-Employee Directors was approved
by the following votes:
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Vote
|
|
87,049,100
|
|
24,191,716
|
|
357,793
|
|
9,952,259
|
About Quest Diagnostics Incorporated (NYSE:DGX)
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others. The Company’s Diagnostic Solutions offers a range of solutions for insurers and healthcare providers. The Company provides risk assessment services for the life insurance industry. In addition, the Company offers healthcare organizations and clinicians’ health information technology solutions and diagnostic products. ExamOne provides risk assessment services to the life insurance industry in North America. ChartMaxx is the Company’s enterprise content management system for hospitals. Quest Diagnostics Incorporated (NYSE:DGX) Recent Trading Information
Quest Diagnostics Incorporated (NYSE:DGX) closed its last trading session up +0.18 at 105.89 with 877,855 shares trading hands.
